Right to Try in Oman

How the right to try pathway operates in Oman.

About Right to Try

US federal legislation (2018) providing an alternative pathway to investigational drugs.

How Right to Try works in Oman

Oman's MoH operates a personal-import pathway; volumes are smaller but the pathway is functional for rare-disease and specialty needs.

Patients in Oman seeking access under Right to Try typically follow this flow: a licensed physician in Oman issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in Oman

  • Physician prescription and clinical-justification letter.
  • Patient identification and consent.
  • Country-specific NPP/personal-import form.
  • Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 2 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Right to Try in Oman

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp